Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses

Zhou, Kali; Fitzpatrick, Thomas; Walsh, Nick; Kim, Ji Young; Chou, Roger; Lackey, Mellanye; Scott, Julia; Lo, Ying Ru; Tucker, Joseph D.

doi:10.1016/s1473-3099(16)30208-0

Cited by 136 publications

(128 citation statements)

References 82 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Potential strategies to improve HCV testing include education and counseling by health professionals with on-site HCV testing (Cullen et al, 2006; Lacey, Ellen, Devlin, Wright, & Mijch, 2007; Meyer et al, 2015; Rosenberg et al, 2010; Sahajian et al, 2011; Zhou et al, 2016), physical and electronic medical chart reminders to prompt targeted risk-based assessment and testing (Drainoni et al, 2012; Krauskopf et al, 2014; Litwin et al, 2012; Meyer et al, 2015; Zhou et al, 2016), and simplified testing, including dried blood spot testing (Abou-Saleh, Rice, & Foley, 2013; Coats & Dillon, 2015; Craine, O'Toole, D'Arcy, & Lyons, 2009; Hickman et al, 2008; McLeod et al, 2014; Meyer et al, 2015; Tait, Stephens, McIntyre, Evans, & Dillon, 2013; Zhou et al, 2016), and point-of-care HCV testing (Beckwith et al, 2016; Bottero et al, 2015; Morano et al, 2014). …”

Section: Hcv Testingmentioning

confidence: 99%

“…Although finger-stick dried blood spot testing enhances HCV testing (Abou-Saleh, et al, 2013; Coats & Dillon, 2015; Craine et al, 2009; Hickman et al, 2008; McLeod et al, 2014; Meyer et al, 2015; Tait et al, 2013; Zhou et al, 2016), collection cards need to be sent somewhere for testing at centralized diagnostic laboratories requiring people to come back for a second visit to receive their result. Among HIV-infected gay and bisexual men, innovative approaches using on-line ordering with self-collected dried blood spot testing simplifies testing and improves access to marginalized populations (Terrence Higgins Trust, 2016).…”

Section: Hcv Testingmentioning

confidence: 99%

“…Simplified HCV testing, including dried blood spot testing (McAllister et al, 2014) and point-of-care HCV testing (Bottero et al, 2015; Morano et al, 2014) has been shown to facilitate linkage to HCV care. Other strategies that have been demonstrated to facilitate linkage to HCV care and treatment include, non-invasive liver disease screening using transient elastography (FibroScan ® ) with facilitated referral to care (Foucher et al, 2009; Marshall et al, 2015; Moessner et al, 2011), integrated HCV care (Cullen et al, 2006; Evon et al, 2011; Ho et al, 2015; Knott et al, 2006; Masson et al, 2013; Zhou et al, 2016), patient navigation programs (Falade-Nwulia et al, 2016; Trooskin et al, 2015), and telemedicine (Arora et al, 2011; Lloyd et al, 2013; Mashru, Kirlew, Saginur, & Schreiber, 2017; Tahan, Almashhrawi, Kahveci, Mutrux, & Ibdah, 2016). …”

Section: Linkage To Hcv Care and Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

Grebely

Bruneau

Lazarus

et al. 2017

International Journal of Drug Policy

View full text Add to dashboard Cite

Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7. 5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among those PWID who have ceased injecting. The incidence of HCV infection among current PWID also remains high in many settings. Morbidity and mortality due to liver disease among PWID with HCV infection continues to increase, despite the advent of well-tolerated, simple interferon-free direct-acting antiviral (DAA) HCV regimens with cure rates >95%. As a result of this important clinical breakthrough, there is potential to reverse the rising burden of advanced liver disease with increased treatment and strive for HCV elimination among PWID. Unfortunately, there are many gaps in knowledge that represent barriers to effective prevention and management of HCV among PWID. The Kirby Institute, UNSW Sydney and the International Network on Hepatitis in Substance Users (INHSU) established an expert round table panel to assess current research gaps and establish future research priorities for the prevention and management of HCV among PWID. This round table consisted of a one-day workshop held on 6 September, 2016, in Oslo, Norway, prior to the International Symposium on Hepatitis in Substance Users (INHSU 2016). International experts in drug and alcohol, infectious diseases, and hepatology were brought together to discuss the available scientific evidence, gaps in research, and develop research priorities. Topics for discussion included the epidemiology of injecting drug use, HCV, and HIV among PWID, HCV prevention, HCV testing, linkage to HCV care and treatment, DAA treatment for HCV infection, and reinfection following successful treatment. This paper highlights the outcomes of the roundtable discussion focused on future research priorities for enhancing HCV prevention, testing, linkage to care and DAA treatment for PWID as we strive for global elimination of HCV infection.

show abstract

Section: Hcv Testingmentioning

confidence: 99%

Section: Hcv Testingmentioning

confidence: 99%

Section: Linkage To Hcv Care and Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

Grebely

Bruneau

Lazarus

et al. 2017

International Journal of Drug Policy

View full text Add to dashboard Cite

show abstract

“…Indeed, developing a standardised monitoring approach for interventions including diagnosis and treatment along the continuum of care, which is already established for HIV, could now be considered for hepatitis B and C. A recent review of operational interventions along the chronic viral hepatitis care continuum for people with diagnosed or undiagnosed chronic viral hepatitis demonstrated that a range of relatively simple, inexpensive operational interventions can substantially improve engagement and retention along the cascade of care, thereby optimising the implementation of screening, care, and treatment programmes [31]. …”

Section: The European Situationmentioning

confidence: 99%

Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions

et al. 2017

View full text Add to dashboard Cite

The World Health Organization ‘Global Health Sector Strategy on Viral Hepatitis 2016–2021’ aimed at the elimination of viral hepatitis as a public health threat provides a significant opportunity to increase efforts for tackling the epidemics of hepatitis B and hepatitis C virus infections across Europe. To support the implementation and monitoring of this strategy, core epidemiological and programmatic indicators have been proposed necessitating specific surveys, the systematic collection of programmatic data and the establishment of monitoring across the care pathway. European Union and European Economic Area countries already made progress in recent years implementing primary and secondary prevention measures. Indeed, harm reduction measures among people who inject drugs reach many of those who need them and most countries have a universal hepatitis B vaccination programme with high coverage above 95%. However, while a further scaling up of prevention interventions will impact on incidence of new infections, treating those already infected is necessary to achieve reductions in mortality. The epidemiological, demographic and socio-political situation in Europe is complex, and considerable diversity in the programmatic responses to the hepatitis epidemic exists. Comprehension of such issues alongside collaboration between key organisations and countries will underpin any chance of successfully eliminating hepatitis.

show abstract

“…It was also mentioned by some patients that they are not comfortable to receive HCV treatment at OST clinics . In a systematic review, it was demonstrated that co‐location of HCV treatment with mental health and addiction services cannot significantly improve the treatment uptake . Treatment uptake between 0% and 60% (median 30%) was reported among PWID and between 24% and 76% (median 55%) among PWID plus additional criteria, for example HCV genotype or drug use status .…”

Section: Discussionmentioning

confidence: 99%

Clinical effectiveness, cost effectiveness and acceptability of community‐based treatment of hepatitis C virus infection: A mixed method systematic review

Pourmarzi

Hall

Hepworth

et al. 2019

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Summary Several community‐based models for treating hepatitis C virus (HCV) infection have been implemented to improve treatment accessibility and health outcomes. However, there is a lack of knowledge regarding how well these models achieve the desired goals. We conducted a mixed‐method systematic review of quantitative and qualitative evidence about clinical effectiveness, cost effectiveness and acceptability of community‐based HCV treatment models. Seventeen databases were researched for published and unpublished studies. Methodological quality was assessed using The Joanna Briggs Institute Critical Appraisal tools. Quantitative findings were synthesized in narrative form and qualitative findings were synthesized using meta‐synthesis. Forty‐two quantitative and six qualitative studies were included. No relevant cost effectiveness studies were found. Five categories of community‐based models were identified: telehealth, integration of HCV and addiction services, integration of HCV and HIV services, integration of HCV and primary care, and implementation by a home care and health care management company. The range of reported outcomes included; end of treatment response: 48.7% to 96%, serious side effects: 3.3% to 27.8%, sustained virological response: 22.3% to 95.5%, relapse: 2.2% to 16.7%, and treatment completion: 33.4% to 100%. Inconsistent measures of uptake and adherence were used; uptake ranged from 8.3% to 92%, and 68.4% to 100% of patients received ≥80% of prescribed doses. Patient reported experiences included trusted and supportive care providers, safe and trusted services, easily accessible care, and positive psychological and behavioural changes. The clinical effectiveness and acceptability reported from the included studies are similar to or better than reported outcomes from systematic reviews of studies in tertiary settings. Studies of the cost effectiveness of community‐based models for treating HCV are needed.

show abstract

Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses

Abstract: World Health Organization and US Fulbright Program.

Cited by 136 publications

References 82 publications

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions

Clinical effectiveness, cost effectiveness and acceptability of community‐based treatment of hepatitis C virus infection: A mixed method systematic review

Contact Info

Product

Resources

About